Literature DB >> 15520057

Chemotherapy for patients with hormone-refractory prostate cancer.

F Joly, I F Tannock.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15520057     DOI: 10.1093/annonc/mdh445

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

1.  Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications.

Authors:  Arun Bhardwaj; Seema Singh; Sanjeev K Srivastava; Richard E Honkanen; Eddie Reed; Ajay P Singh
Journal:  Mol Cancer Ther       Date:  2011-03-10       Impact factor: 6.261

2.  Current treatment strategies for castration-resistant prostate cancer.

Authors:  Se Joong Kim; Sun Il Kim
Journal:  Korean J Urol       Date:  2011-03-18

3.  New multidisciplinary prostate bone metastases clinic: first of its kind in Canada.

Authors:  P Goh; K Harris; J Napolskikh; E Chow; E Sinclair; U Emmenegger; S Lemon; A Yee; L Wynnychuk; J Myers; C Danjoux; Y Ko
Journal:  Curr Oncol       Date:  2007-02       Impact factor: 3.677

4.  Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model.

Authors:  A Bhardwaj; S Singh; S K Srivastava; S Arora; S J Hyde; J Andrews; W E Grizzle; A P Singh
Journal:  Br J Cancer       Date:  2014-03-18       Impact factor: 7.640

5.  A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer.

Authors:  Sang Eun Yoon; Youjin Kim; Jangho Cho; Minyong Kang; Hyun Hwan Sung; Hwang Gyun Jeon; Byoung Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Han Yong Choi; Su Jin Lee; Se Hoon Park
Journal:  BMC Urol       Date:  2019-05-03       Impact factor: 2.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.